https://observatorio.fm.usp.br/handle/OPI/33670
DC Field | Value | Language |
---|---|---|
dc.contributor | Sistema FMUSP-HC: Faculdade de Medicina da Universidade de São Paulo (FMUSP) e Hospital das Clínicas da FMUSP | |
dc.contributor.author | LEVI, Jose Eduardo | |
dc.contributor.author | MARTINS, Toni Ricardo | |
dc.contributor.author | LONGATTO-FILHO, Adhemar | |
dc.contributor.author | COHEN, Diane Dede | |
dc.contributor.author | CURY, Use | |
dc.contributor.author | FUZA, Luiz Mario | |
dc.contributor.author | VILLA, Luisa L. | |
dc.contributor.author | ELUF-NETO, Jose | |
dc.date.accessioned | 2019-09-23T15:00:22Z | - |
dc.date.available | 2019-09-23T15:00:22Z | - |
dc.date.issued | 2019 | |
dc.identifier.citation | CANCER PREVENTION RESEARCH, v.12, n.8, p.539-546, 2019 | |
dc.identifier.issn | 1940-6207 | |
dc.identifier.uri | https://observatorio.fm.usp.br/handle/OPI/33670 | - |
dc.description.abstract | Every year there are approximately 16,000 new cases of cervical cancer in Brazil. Novel screening technologies may reduce this number by expanding the population coverage but also by improving the detection rate of precursor lesions. We aimed to evaluate human papillomaviruses (HPV)-DNA testing in the context of routine cervical cancer screening in the public health system of the city of Sao Paulo, Brazil. Women participating in the primary screening program were invited to enroll. Liquid-based cytology samples were collected and cytology and Hr-HPV DNA testing were performed in parallel. Cytologists were blind to I IPV results. Women older than 24 years with a positive high-risk HPV test and/or cytology class >= ASC-US were referred to colposcopy. From December 2014 to December 2016, 16,102 women joined the study. High-risk human papillomavirus (HR HPV) DNA prevalence was 14.9%, whereas cytologic abnormalities were found in 7,2% of the women. Per protocol, 1,592 Hr-HPV+ women, in addition to 72 patients with cytologic classification > low-grade squamous intraepithelial lesion (LSIL) were referred. A total of 80 cervical intraepithelial neoplasia (CIN2(+)) cases were diagnosed, 79 were Hr-HPV DNA(+) and 18 had normal cytology. Hr-HPV DNA detected a significant number of patients with premalignant lesions missed by cytology and all 16 CIN3(+) cases were Hr-HPV DNA(+). HPV genotyping may be useful in the management of Hr-HPV+ women, reducing the burden of colposcopic referral for those harboring genotypes with a weaker association to CIN3(+). Use of HPV-DNA testing was shown to be feasible and advantageous over current cytologic screening in the public health system. | eng |
dc.description.sponsorship | National Research Council (CNPq) [573799/2008-3] | |
dc.description.sponsorship | Sao Paulo Research Foundation (FAPESP) [2008/57889-1] | |
dc.language.iso | eng | |
dc.publisher | AMER ASSOC CANCER RESEARCH | eng |
dc.relation.ispartof | Cancer Prevention Research | |
dc.rights | restrictedAccess | eng |
dc.subject.other | women | eng |
dc.subject.other | neoplasia | eng |
dc.title | High-Risk HPV Testing in Primary Screening for Cervical Cancer in the Public Health System, Sao Paulo, Brazil | eng |
dc.type | article | eng |
dc.rights.holder | Copyright AMER ASSOC CANCER RESEARCH | eng |
dc.identifier.doi | 10.1158/1940-6207.CAPR-19-0076 | |
dc.identifier.pmid | 31189569 | |
dc.subject.wos | Oncology | eng |
dc.type.category | original article | eng |
dc.type.version | publishedVersion | eng |
hcfmusp.author.external | COHEN, Diane Dede:Fundacao Oncoctr Sao Paulo, Sao Paulo, Brazil | |
hcfmusp.author.external | CURY, Use:Fundacao Oncoctr Sao Paulo, Sao Paulo, Brazil | |
hcfmusp.description.beginpage | 539 | |
hcfmusp.description.endpage | 546 | |
hcfmusp.description.issue | 8 | |
hcfmusp.description.volume | 12 | |
hcfmusp.origem | WOS | |
hcfmusp.origem.id | WOS:000478016000005 | |
hcfmusp.origem.id | 2-s2.0-85070559488 | |
hcfmusp.publisher.city | PHILADELPHIA | eng |
hcfmusp.publisher.country | USA | eng |
hcfmusp.relation.reference | Costa RFA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138945 | eng |
hcfmusp.relation.reference | Arbyn M, 2015, CLIN MICROBIOL INFEC, V21, P817, DOI 10.1016/j.cmi.2015.04.015 | eng |
hcfmusp.relation.reference | Silva GAE, 2010, CAD SAUDE PUBLICA, V26, P2398 | eng |
hcfmusp.relation.reference | Cuschieri K, 2018, INT J CANCER, V143, P735, DOI 10.1002/ijc.31261 | eng |
hcfmusp.relation.reference | Diaz RS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139677 | eng |
hcfmusp.relation.reference | Ejegod D, 2016, J CLIN MICROBIOL, V54, P2267, DOI 10.1128/JCM.00508-16 | eng |
hcfmusp.relation.reference | Flores YN, 2011, CANCER CAUSE CONTROL, V22, P261, DOI 10.1007/s10552-010-9694-3 | eng |
hcfmusp.relation.reference | Forman D, 2013, CANC INCIDENCE 5 CON | eng |
hcfmusp.relation.reference | Gultekin M, 2018, INT J CANCER, V142, P1952, DOI 10.1002/ijc.31212 | eng |
hcfmusp.relation.reference | Instituto Nacional de Cancer (Brasil), 2011, COORD GER AC ESTR | eng |
hcfmusp.relation.reference | Instituto Nacional de Cancer Jose Alencar Gomes da Silva, 2016, COORDENACAO DE PREVE | eng |
hcfmusp.relation.reference | Jeronimo J, 2016, J CLIN VIROL, V76, pS69, DOI 10.1016/j.jcv.2015.11.035 | eng |
hcfmusp.relation.reference | Kurman R, 2014, WHO CLASSIFICATION T | eng |
hcfmusp.relation.reference | Lew JB, 2017, LANCET PUBLIC HEALTH, V2, pE96, DOI 10.1016/S2468-2667(17)30007-5 | eng |
hcfmusp.relation.reference | Longatto A, 2015, ACTA CYTOL, V59, P273, DOI 10.1159/000435801 | eng |
hcfmusp.relation.reference | Martins TR, 2018, AM J CLIN PATHOL, V149, P316, DOI [10.1093/ajcp/aqx163, 10.1093/AJCP/AQX163] | eng |
hcfmusp.relation.reference | Nayar R, 2015, CANCER CYTOPATHOL, V123, P271, DOI 10.1002/cncy.21521 | eng |
hcfmusp.relation.reference | Rocha D, 2018, TRANSFUSION, V58, P862, DOI 10.1111/trf.14478 | eng |
hcfmusp.relation.reference | Ronco G, 2014, LANCET, V383, P524, DOI 10.1016/S0140-6736(13)62218-7 | eng |
hcfmusp.relation.reference | Schiffman M, 2011, CANCER EPIDEM BIOMAR, V20, P1398, DOI 10.1158/1055-9965.EPI-11-0206 | eng |
hcfmusp.relation.reference | Smelov V, 2015, INT J CANCER, V136, P1171, DOI 10.1002/ijc.29085 | eng |
hcfmusp.relation.reference | Speck NMG, 2018, DOSSIE ESTRATEGIAS R | eng |
hcfmusp.relation.reference | Stoler MH, 2018, GYNECOL ONCOL, V149, P498, DOI 10.1016/j.ygyno.2018.04.007 | eng |
hcfmusp.relation.reference | Thomsen LT, 2015, INT J CANCER, V137, P193, DOI 10.1002/ijc.29374 | eng |
hcfmusp.relation.reference | Torres KL, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0201262 | eng |
hcfmusp.relation.reference | Wentzensen N, 2017, INT J CANCER, V140, P2192, DOI 10.1002/ijc.30579 | eng |
hcfmusp.relation.reference | Wright TC, 2015, GYNECOL ONCOL, V136, P189, DOI 10.1016/j.ygyno.2014.11.076 | eng |
hcfmusp.relation.reference | Wright TC, 2011, AM J CLIN PATHOL, V136, P578, DOI 10.1309/AJCPTUS5EXAS6DKZ | eng |
dc.description.index | MEDLINE | eng |
dc.identifier.eissn | 1940-6215 | |
hcfmusp.citation.scopus | 11 | - |
hcfmusp.scopus.lastupdate | 2024-03-29 | - |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MDR Artigos e Materiais de Revistas Científicas - FM/MPR Artigos e Materiais de Revistas Científicas - IMT Artigos e Materiais de Revistas Científicas - LIM/14 Artigos e Materiais de Revistas Científicas - LIM/24 Artigos e Materiais de Revistas Científicas - LIM/38 Artigos e Materiais de Revistas Científicas - LIM/52 Artigos e Materiais de Revistas Científicas - ODS/03 |
File | Description | Size | Format | |
---|---|---|---|---|
art_LEVI_HighRisk_HPV_Testing_in_Primary_Screening_for_Cervical_2019.PDF Restricted Access | publishedVersion (English) | 267.04 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.